FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study

European Journal of Surgical Oncology

Volumn 42, Issue 10, 2016, Pages 1540-1547

  Kohne C H ^a   Poston, G ^b   Folprecht, G ^c   Ciardiello, F ^d   Ronga, P ^e   Beier, F ^e   Van Cutsem, E ^f  

^a UNIVERSITY OF OLDENBURG   (Germany)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e MERCK KGAA   (Germany)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cetuximab; CRYSTAL; LLD; mCRC; R0 resection; RAS

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; RAS PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT RESPONSE; WILD TYPE; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; ONCOGENE RAS; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENES, RAS; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES;

EID: 84989883694     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2016.05.038     Document Type: Article

References (21)

1. 1 Kopetz, S., Chang, G.J., Overman, M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:22 (2009), 3677–3683.
2. 2 Kanas, G.P., Taylor, A., Primrose, J.N., et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 4 (2012), 283–301.
3. 3 Nordlinger, B., Adam, R., Arnold, D., Zalcberg, J.R., Gruenberger, T., The role of biological agents in the resection of colorectal liver metastases. Clin Oncol (R Coll Radiol) 24:6 (2012), 432–442.
4. 4 Prades, J., Remue, E., van Hoof, E., Borras, J.M., Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy 119:4 (2015), 464–474.
5. 5 Jones, R.P., Vauthey, J.N., Adam, R., et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 99:9 (2012), 1263–1269.
6. 6 Van Cutsem, E., Kohne, C.H., Hitre, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:14 (2009), 1408–1417.
7. 7 Van Cutsem, E., Kohne, C.H., Lang, I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:15 (2011), 2011–2019.
8. 8 Van Cutsem, E., Lenz, H.J., Kohne, C.H., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33:7 (2015), 692–700.
9. 9 Ye, L.C., Liu, T.S., Ren, L., et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31:16 (2013), 1931–1938, 10.1200/JCO.2012.44.8308 [Epub 2013 Apr 8].
10. 10 Folprecht, G., Gruenberger, T., Bechstein, W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:1 (2010), 38–47.
11. 11 Folprecht, G., Gruenberger, T., Bechstein, W., et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 25:5 (2014), 1018–1025.
12. 12 Garufi, C., Torsello, A., Tumolo, S., et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 103:10 (2010), 1542–1547.
13. 13 Malik, H., Khan, A.Z., Berry, D.P., et al. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study. Eur J Surg Oncol 41:4 (2015), 499–505.
14. 14 Truant, S., Sequier, C., Leteurtre, E., et al. Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens. HPB (Oxford) 17:2 (2015), 176–184.
15. 15 Andreou, A., Aloia, T.A., Brouquet, A., et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 257:6 (2013), 1079–1088.
16. 16 Lenz H, Niedzwiecki D, Innocenti F et al. CALGB/SWOG 80405: phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with expanded RAS analyses in untreated metastatic adenocarcinoma of the colon or rectum, ESMO; 2014.
17. 17 Stintzing S, Modest DP, Fischer von Weikersthal L, Decker T. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population, ESMO; 2014 [abstr LBA11].
18. 18 Heinemann, V., von Weikersthal, L.F., Decker, T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:10 (2014), 1065–1075.
19. 19 Venook, A.P., Niedzwiecki, D., Lenz, H.-J., et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol, 32, 2014 5s, suppl; abstr LBA3.
20. 20 Bokemeyer, C., Kohne, C.-H., Ciardiello, F., et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol, 32(5s), 2014 2014 (suppl; abstr 3505).
21. 21 Bokemeyer, C., Bondarenko, I., Hartmann, J.T., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22:7 (2011), 1535–1546.